scholarly journals Correlation Between the Tumor Doubling Time and Histologic Subtypes in Thymic Epithelial Tumors: Is It Possible to Differentiate Between Thymoma and Thymic Carcinoma?

Haigan ◽  
2021 ◽  
Vol 61 (4) ◽  
pp. 297-302
Author(s):  
Koichi Fukumoto ◽  
Madoka Goto ◽  
Yasuhisa Ichikawa ◽  
Yuta Kawasumi ◽  
Mika Uchiyama ◽  
...  
Keyword(s):  
Doubling Time ◽  
Thymic Carcinoma ◽  
Tumor Doubling Time ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Histologic Subtypes

The tumor doubling time is a useful parameter for predicting the histological type of thymic epithelial tumors

Surgery Today ◽  
2019 ◽  
Vol 49 (8) ◽  
pp. 656-660 ◽  
Author(s):  
Koichi Fukumoto ◽  
Takayuki Fukui ◽  
Koji Kawaguchi ◽  
Shota Nakamura ◽  
Shuhei Hakiri ◽  
...  
Keyword(s):  
Doubling Time ◽  
Histological Type ◽  
Tumor Doubling Time ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors

Thymic epithelial tumors at University Federico II of Naples: A 30-year experience.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7603-7603
Author(s):  
Carlo Buonerba ◽  
Piera Federico ◽  
Filomena Calabrese ◽  
Margaret Ottaviano ◽  
Lucia Nappi ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Myasthenia Gravis ◽  
Thymic Carcinoma ◽  
Radical Surgery ◽  
Sample Population ◽  
Tumor Diameter ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Increased Risk ◽  
Thymic Carcinomas

7603 Background: According to the 2004 WHO classification, thymic epithelial tumors (TETs) comprise different histologies, including thymomas, thymic carcinoma, typical and atypical carcinoids. Histology classification of TETs has a dramatic impact on the prognosis and therapeutic strategy. We here review all TETs treated at our Institution over the past 30 years. Methods: Eligible patients had a pathologically confirmed TET and had at least one access at our Institution. Relevant demographic and clinical data were retrieved. An exploratory analysis was conducted using a step-wise model in patients with completely resected tumors to seek for factors predictive of recurrence after radical surgery. Results: One hundred and three patients with TETs were included in this retrospective analysis. Forty-three were female, sixty were male. Median age was 43 years (range 32-58). Forty-three patients had myasthenia gravis. Four had a thymic neuroendrocrine tumor, 19 had a thymic carcinoma, while the remaining had a thymoma. Forty-seven patients were alive at the time of analysis. Median overall survival was 5.85 years (range, 2.58-9.9). In the whole sample population, seventy-six patients had a completely resected tumor with clear pathological margins. In this sub-group of 76 patients (median age: 46, 35-55; 30 females, 46 males), 12 had a thymic carcinoma and 30 patients recurred after radical surgery. At multivariate analysis, which included age, sex, adjuvant chemotherapy, adjuvant radiotherapy, maximum tumor diameter, presence of myasthenia gravis and stage, the only factor significantly predictive of recurrence was tumor histology (odds ratio: 3,8182, 95% CI: 1,03 to 14,1; p = 0.04). Conclusions: We showed that patients with thymic carcinomas are at increased risk of recurrence after radical surgery independently on adjuvant chemotherapy/radiotherapy treatment. Additional therapeutic options are required in the adjuvant setting of completely resected thymic carcinomas.

Does CT of Thymic Epithelial Tumors Enable Us to Differentiate Histologic Subtypes and Predict Prognosis?

2004 ◽  
Vol 183 (2) ◽  
pp. 283-289 ◽  
Author(s):  
Yeon Joo Jeong ◽  
Kyung Soo Lee ◽  
Jhingook Kim ◽  
Young Mok Shim ◽  
Jungho Han ◽  
...  
Keyword(s):  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Histologic Subtypes

scholarly journals Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

2011 ◽  
Vol 29 (15) ◽  
pp. 2052-2059 ◽  
Author(s):  
Giuseppe Giaccone ◽  
Arun Rajan ◽  
Arlene Berman ◽  
Ronan J. Kelly ◽  
Eva Szabo ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Thymic Carcinoma ◽  
Response Rate ◽  
Performance Status ◽  
Hdac Inhibitors ◽  
Primary Objective ◽  
Eligibility Criteria ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Disease Stabilization

Purpose Thymic epithelial tumors are rare malignancies, and there is no standard treatment for patients with advanced disease in whom chemotherapy has failed. Antitumor activity of histone deacetylase (HDAC) inhibitors in this disease has been documented, including one patient with thymoma treated with the pan-HDAC inhibitor belinostat. Patients and Methods Patients with advanced thymic epithelial malignancies in whom at least one line of platinum-containing chemotherapy had failed were eligible for this study. Other eligibility criteria included adequate organ function and good performance status. Belinostat was administered intravenously at 1 g/m2 on days 1 to 5 of a 21-day cycle until disease progression or development of intolerance. The primary objective was response rate in patients with thymoma. Results Of the 41 patients enrolled, 25 had thymoma, and 16 had thymic carcinoma; patients had a median of two previous systemic regimens (range, one to 10 regimens). Treatment was well tolerated, with nausea, vomiting, and fatigue being the most frequent adverse effects. Two patients achieved partial response (both had thymoma; response rate, 8%; 95% CI, 2.2% to 25%), 25 had stable disease, and 13 had progressive disease; there were no responses among patients with thymic carcinoma. Median times to progression and survival were 5.8 and 19.1 months, respectively. Survival of patients with thymoma was significantly longer than that of patients with thymic carcinoma (median not reached v 12.4 months; P = .001). Protein acetylation, regulatory T-cell numbers, and circulating angiogenic factors did not predict outcome. Conclusion Belinostat has modest antitumor activity in this group of heavily pretreated thymic malignancies. However, the duration of response and disease stabilization is intriguing, and additional testing of belinostat in this disease is warranted.

scholarly journals Extracellular volume fraction measurement correlates with lymphocyte abundance in thymic epithelial tumors

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Chao-Chun Chang ◽  
Chia-Ying Lin ◽  
Chang-Yao Chu ◽  
Yi-Cheng Hsiung ◽  
Ming-Tsung Chuang ◽  
...  
Keyword(s):  
T1 Mapping ◽  
Thymic Carcinoma ◽  
Volume Fraction ◽  
Extracellular Volume ◽  
Quantitative Mri ◽  
Low Grade ◽  
Epithelial Tumor ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Thymic Epithelial Tumor

Abstract Background Recent advance in tissue characterization with parametric mapping imaging has the potential to be a novel biomarker for histopathologic correlation with thymic epithelial tumors (TETs). The purpose of our study is to evaluate MRI T1 mapping with the calculation of extracellular volume (ECV) fraction for histologic correlation with thymic epithelial tumor based on lymphocyte abundance. Methods A retrospective study including 31 consecutive patients (14 men and 17 women, median age, 56 years; interquartile range, 12 years) with TETs was performed. The T1 values and ECV were assessed by using quantitative MRI mapping techniques. Mann-Whitney U test, Kruskal-Wallis H test, and receiver operating characteristic curve analyses were used to assess discrimination between different types of TETs based on lymphocyte abundance. Results Extracellular volume was significantly higher in TETs with sparse lymphocyte, including type A, type B3, and thymic carcinoma, compared with those with abundant lymphocyte, including type B1, B2, and AB thymomas (42.5% vs 26.9%, respectively; p < 0.001). Extracellular volume was significantly higher in thymic carcinoma compared with low grade and high grade thymomas (48.6% vs 31.1% vs 27.6%, respectively; p = 0.002). Conclusions T1 mapping with the calculation of extracellular volume (ECV) fraction correlate with the WHO histologic classification of thymic epithelial tumor based on lymphocyte abundance.

MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma

2011 ◽  
Vol 458 (5) ◽  
pp. 615-620 ◽  
Author(s):  
Kyoichi Kaira ◽  
Haruyasu Murakami ◽  
Masakuni Serizawa ◽  
Yasuhiro Koh ◽  
Masato Abe ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Thymic Carcinoma ◽  
Muc1 Expression ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors

JOURNAL CLUB: Doubling Time of Thymic Epithelial Tumors Correlates With World Health Organization Histopathologic Classification

2017 ◽  
Vol 209 (4) ◽  
pp. W202-W210 ◽  
Author(s):  
Dong Young Jeong ◽  
Kyung Soo Lee ◽  
Myung Jin Chung ◽  
Jae Ill Zo ◽  
Young Mog Shim ◽  
...  
Keyword(s):  
World Health Organization ◽  
Doubling Time ◽  
Journal Club ◽  
World Health ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Health Organization

scholarly journals Cutaneous Metastasis of Thymic Carcinoma to the Frontal Scalp

2021 ◽  
Vol 5 (4) ◽  
pp. 441-444
Author(s):  
Leon Kou ◽  
Austin Wong ◽  
Lily Zhong ◽  
Sid Danesh
Keyword(s):  
Mortality Rate ◽  
Lymph Nodes ◽  
Rare Variant ◽  
Thymic Carcinoma ◽  
Cutaneous Metastasis ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
Carcinoma Metastasis ◽  
Lung Lymph ◽  
Thymic Carcinomas

Thymic carcinomas are a rare variant of thymic epithelial tumors.  Compared to thymomas, they are much more aggressive, difficult to treat, and have a higher mortality rate.  Metastasis outside of the mediastinum is rare and usually to sites such as the lung, lymph nodes, liver, pleura, or bones.  We report a case of immunohistochemistry proven thymic carcinoma metastasis to the cutaneous surface of the frontal scalp in a 53-year-old Asian female.

Sign in / Sign up

Export Citation Format

Share Document